Sen. Grassley: Justice Department Settlement on EpiPen Overcharges is Disappointment to Taxpayers
August 17, 2017
August 17, 2017
WASHINGTON, Aug. 17 -- The office of Sen. Charles E. Grassley, R-Iowa, issued the following news release:
Sen. Chuck Grassley of Iowa has been investigating the cost increases for EpiPen to consumers and whether the taxpayers have been shortchanged under EpiPen's misclassification under the Medicaid Drug Rebate Program. He made the following comment today on a settlement announced between the Justice Department and EpiPen maker Mylan over the misclassification. The case is a False C . . .
Sen. Chuck Grassley of Iowa has been investigating the cost increases for EpiPen to consumers and whether the taxpayers have been shortchanged under EpiPen's misclassification under the Medicaid Drug Rebate Program. He made the following comment today on a settlement announced between the Justice Department and EpiPen maker Mylan over the misclassification. The case is a False C . . .